Is Palantir Sell-Off Over?
Last Wednesday, August 20, was the day that the potential rebound in Palantir (PLTR) took place. The stock looked like it would fall below $140. Fortunately, stock markets staged a strong relief rally last Friday.Optimism rose after Fed Chair Powell spoke at the Jackson Symposium. The rally lifted the Magnificent Seven firms, including Tesla (TSLA), Alphabet (GOOG), and Amazon (AMZN). After Palantir shares pulled back a few days ago, is the sell-off over?Palantir’s excessive valuations are a near-term risk. Its uptrend toward $200 depends on Nasdaq (QQQ) continuing its rise. To justify the index’s high P/E, investors need the central bank to cut rates more than once this year.Strong GrowthPalantir demonstrated its ability to maximize growth in artificial intelligence. In the last quarter, government revenue grew by 53%. Expect its oldest customer, the U.S. Army, to continue to reward Palantir with multi-billion-dollar contracts. It needs the data and software to achieve efficiencies and to support growth in the military.Global conflicts show no signs of slowing down. This will require the U.S. government to continue increasing its spending on products that Palantir offers.Investors may consider other tech firms that trade at a lower P/E in the 20 times to 40 times range. This includes Nvidia (NVDA), Microsoft (MSFT), Broadcom (AVGO), AMD (AMD), and IBM (IBM).
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


